UCB announces 21 data presentations spanning clinical research and real-world insights at AES 2025
UCB, a global biopharmaceutical company, today announced it will present 21 abstracts at the American Epilepsy Society (AES) Annual Meeting (December 5-9, 2025). Data include primary efficacy and… read more.
